Home
Live Updates
LNK01001 Achieves Primary End Point in Phase II Trial for Atopic Dermatitis : vimarsana.com
LNK01001 Achieves Primary End Point in Phase II Trial for Atopic Dermatitis
Patients given LNK01001 showed significant improvement in Eczema Area and Severity Index scores over placebo.
Related Keywords
Peking ,
Beijing ,
China ,
Chinese ,
Jianzhong Zhang ,
Lynk Pharmaceuticals Co Ltd ,
Dermatology Division Of The Chinese Medical Association ,
Dermatology Department At Peking University People Hospital ,
Eczema Area ,
Severity Index ,
Global Assessment ,
Dermatology Division ,
Chinese Medical Association ,
Dermatology Department ,
Peking University People ,
Common Terminology Criteria ,
vimarsana.com © 2020. All Rights Reserved.